Alkem Laboratories Ltd - Company Profile
Powered by
All the data and insights you need on Alkem Laboratories Ltd in one report.
- Save hours of research time and resources with
our up-to-date Alkem Laboratories Ltd Strategy Report
- Understand Alkem Laboratories Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Business Description
Alkem Laboratories Ltd (Alkem) provides active pharmaceutical ingredients (APIs) products, nutraceuticals, generic and branded products, biologics & biosimilars in advanced dosage forms complying with cGMP requirements. Its portfolio encompasses products in the therapeutic areas of CNS, dermatology, anti-infectives, pain and analgesic, anti-diabetic, gynecology, gastro-intestinal, cardiac, respiratory, vitamins, minerals, and nutrients.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
Alkem focuses on making substantial investments and strengthening its research and development capabilities. R&D is the key component of the company’s business continuity plans. Alkem’s R&D team comprises more than 500 scientists who strive to continuously develop new products with cutting-edge technology at its five R&D centres across India and the US. The company spent INR5,394 million in R&D activities during FY2023, which as a percentage of revenue stood at 4.6%. All the R&D centers are equipped with state-of-the-art infrastructure and have been accredited by international regulatory authorities namely WHO, US FDA, MHRA (UK), ANVISA (Brazil), TGA (Australia) and MCC (South Africa). The company also invests in biosimilars segment through its subsidiary Enzene Biosciences. In FY2023, Alkem filed 175 Abbreviated New Drug Applications (ANDAs) with the US FDA, including NDAs, and received 134 approvals including tentative approvals.
Geographical Segments
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward